More than TWO,000 XIENCE V Patients May Also Be Eligible to Join Industry-Wide Trial Studying Optimal Duration of Dual Anti-Platelet Therapy ABBOTT PARK, Ill., Aug. 13 (HSMN NewsFeed) — Abbott (NYSE: ABT ) today announced the expansion of the company’s…
Devices, Interventional Cardiology
Abbott, XIENCE V, Everolimus, drug eluting stent, anti-platelet

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial”
Leave a Comment